<div id="readability-page-1"><ul><li>MarketBeat Week in Review – 7/10 - 7/14</li></ul><p>Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.38) for the year, up from their prior estimate of ($1.57). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.30) EPS, FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($0.72) EPS.</p><div><p><span></span><span>Get <strong>Caribou Biosciences</strong> alerts:</span></p></div><p>Other research analysts have also recently issued research reports about the company. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Caribou Biosciences in a research note on Wednesday, October 8th. Citigroup lifted their price objective on Caribou Biosciences from $5.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, November 3rd. Wall Street Zen raised Caribou Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 24th. Truist Financial  set a $7.00 price target on shares of Caribou Biosciences in a report on Tuesday, November 4th. Finally, HC Wainwright lifted their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, Caribou Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.75.</p><ul><li>3 Biotech Stocks to Buy for Long-Term Gains</li></ul><p><b>Read Our Latest Research Report on Caribou Biosciences</b></p><h2>Caribou Biosciences Trading Up 0.3%</h2><p>CRBU stock opened at $1.99 on Monday. The stock has a market capitalization of $186.01 million, a PE ratio of -1.17 and a beta of 2.59. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.54. The stock's 50 day simple moving average is $2.24 and its 200 day simple moving average is $1.76. </p><ul><li>Pfizer Just Invested $25 million In This Biotech</li></ul><p>Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.20 million for the quarter, compared to the consensus estimate of $1.94 million. Caribou Biosciences had a negative net margin of 1,690.45% and a negative return on equity of 69.85%. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC lifted its position in shares of  Caribou Biosciences by 163.6% in the first quarter. Cerity Partners LLC now owns 40,722 shares of the company's stock valued at $37,000 after acquiring an additional 25,271 shares in the last quarter.  Nelson Capital Management LLC raised its stake in  Caribou Biosciences by 31.1% during the 1st quarter. Nelson Capital Management LLC now owns 85,020 shares of the company's stock valued at $78,000 after purchasing an additional 20,162 shares during the period.  Nuveen LLC purchased a new position in  Caribou Biosciences in the 1st quarter worth approximately $302,000.  Aberdeen Group plc boosted its stake in  Caribou Biosciences by 126.5% in the 1st quarter. Aberdeen Group plc now owns 411,144 shares of the company's stock worth $375,000 after purchasing an additional 229,657 shares during the period.  Finally, Pale Fire Capital SE grew its holdings in  Caribou Biosciences by 7.2% during the 1st quarter. Pale Fire Capital SE now owns 786,722 shares of the company's stock valued at $718,000 after buying an additional 52,518 shares in the last quarter. Hedge funds and other institutional investors own  77.51% of the company's stock. </p><h2>About Caribou Biosciences</h2> (Get Free Report)<p>Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Caribou Biosciences</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCVQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCVQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Caribou Biosciences Right Now?</h2><p>Before you consider Caribou Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.</p><p>While Caribou Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRBU

<p>Leerink Partners raised their FY2025 EPS estimates for Caribou Biosciences to ($1.38) from ($1.57). The consensus estimate for the current year is ($1.64). Other analysts have varied ratings, with a consensus of 'Moderate Buy' and an average price target of $8.75. Caribou Biosciences focuses on genome-edited cell therapies, with its lead product in phase 1 trials.</p>

FY2025 Earnings Forecast for CRBU Issued By Leerink Partnrs